Prescient Therapeutics
Prescient Therapeutics is a clinical-stage oncology company that specializes in the development of novel drugs that provide treatment options for a variety of cancer types. The company's primary focus is on the development of personalized therapies that target the specific needs of individual patients.
History[edit | edit source]
Prescient Therapeutics was founded with the aim of developing and commercializing novel, targeted therapies for the treatment of a range of different cancers. The company's approach is based on the understanding that each patient's cancer is unique and requires a personalized treatment strategy.
Research and Development[edit | edit source]
Prescient Therapeutics' research and development efforts are focused on the discovery and development of novel, targeted therapies for the treatment of cancer. The company's pipeline includes a number of promising drug candidates that are currently in various stages of clinical development.
PTX-100[edit | edit source]
PTX-100 is a first-in-class compound that blocks the RhoA and RhoC proteins, which are involved in cancer cell growth and survival. PTX-100 has shown promising results in early-stage clinical trials for the treatment of certain types of leukemia and lymphoma.
PTX-200[edit | edit source]
PTX-200 is a novel phosphatidylinositol 3-kinase (PI3K) inhibitor that has shown potential in preclinical and early-stage clinical trials for the treatment of certain types of breast cancer, ovarian cancer, and leukemia.
Clinical Trials[edit | edit source]
Prescient Therapeutics is currently conducting a number of clinical trials to evaluate the safety and efficacy of its drug candidates. These trials are being conducted in collaboration with leading cancer centers and research institutions around the world.
Future Directions[edit | edit source]
Prescient Therapeutics continues to explore new avenues for the development of novel, targeted therapies for the treatment of cancer. The company's ongoing research and development efforts are aimed at identifying new drug candidates and advancing its existing pipeline through clinical development.
See Also[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
